Non-cancerous CT findings as predictors of survival outcome in advanced non-small cell lung cancer patients treated with first-generation EGFR-TKIs

0Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Purpose To identify non-cancerous factors from baseline CT chest affecting survival in advanced non-small cell lung cancer (NSCLC) treated with first-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (EGFR-TKIs). Methods Retrospective study of 172 advanced NSCLC patients treated with first-generation EGFR-TKIs as a first-line systemic treatment (January 2012 to September 2022). Baseline CT chest assessed visceral/subcutaneous fat (L1 level), sarcopenia, and myosteatosis (multiple levels), main pulmonary artery (MPA) size, MPA to aorta ratio, emphysema, and bone mineral density. Cox regression analyzed prognostic factors at 18-month outcome. Results Median overall survival was 17.57 months (14.87–20.10) with 76 (44.19%) patients died at 18 months. Deceased had lower baseline BMI (21.10 ± 3.44) vs. survived (23.25 ± 4.45) (p < 0.001). Univariable analysis showed 5 significant prognostic factors: low total adiposity with/without cutoff [HR 2.65 (1.68–4.18), p < 0.001; 1.00 (0.99–1.00), p = 0.006;], low subcutaneous adipose tissue (SAT) with/without cutoff [HR 1.95 (1.23–3.11), p = 0.005; 0.99 (0.98–0.99), p = 0.005], low SAT index (SATI) with/without cutoff [1.74 (1.10–2.78), p = 0.019; 0.98 (0.97–0.99), p = 0.003], high VSR [1.67 (1.06–2.62), p = 0.026], and high MPA size with/without cutoff [2.23 (1.23–4.04), p = 0.005; 1.09 (1.04–1.16), p = 0.001]. MPA size, MPA size > 29 mm, and total adiposity ≤85 cm2 remained significant in multivariable analysis, adjusted by BMI [HR 1.14 (1.07–1.21), p < 0.001; 3.10 (1.81–5.28), p < 0.001; 3.91 (1.63–9.40), p = 0.002]. There was no significant difference of sarcopenic and myosteatotic parameters between the two groups. Conclusion In advanced EGFR-mutated NSCLC patients, assessing pre-treatment prognosis is warranted to predict the survival outcome and guide decision regarding EGFR-TKI therapy. Enlarged MPA size, low total adiposity, and low subcutaneous fat (lower SAT, lower SATI, and higher VSR) are indicators of poor survival. Large MPA size (>29 mm) or low total adiposity (≤85 cm2) alone predict 18-month death.

Cite

CITATION STYLE

APA

Prakaikietikul, P., Tajarenmuang, P., Losuriya, P., Ina, N., Ketpueak, T., & Kanthawang, T. (2025). Non-cancerous CT findings as predictors of survival outcome in advanced non-small cell lung cancer patients treated with first-generation EGFR-TKIs. PLoS ONE, 20(2 February). https://doi.org/10.1371/journal.pone.0313577

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free